75061
Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate
≥95.0% (CHN)
Synonym(s):
DOTA-tri-t-Bu-ester
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
assay
≥95.0% (CHN)
form
lumps
functional group
carboxylic acid
ester
SMILES string
CC(C)(C)OC(=O)CN1CCN(CCN(CCN(CC1)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(O)=O
InChI
1S/C28H52N4O8/c1-26(2,3)38-23(35)19-30-12-10-29(18-22(33)34)11-13-31(20-24(36)39-27(4,5)6)15-17-32(16-14-30)21-25(37)40-28(7,8)9/h10-21H2,1-9H3,(H,33,34)
InChI key
RVUXZXMKYMSWOM-UHFFFAOYSA-N
Related Categories
Application
Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (tri BOC-DOTA) can be employed as a reactant to prepare:
- Gadolinium ion functionalized with DOTA-LAE (lactobionic acid-ethylenediamine), which is used as a contrast agent for magnetic resonance imaging (MRI).
- DOTA-conjugates of ursolic acid and ZD2 peptide 64Cu-DOTA conjugates.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Biomolecules, 10(3) (2020-03-25)
Overexpression of G protein-coupled receptors (GPCRs) in tumours is widely used to develop GPCR-targeting radioligands for solid tumour imaging in the context of diagnosis and even treatment. The human vasoactive neuropeptide urotensin II (hUII), which shares structural analogies with somatostatin
Synthesis of a gadolinium based-macrocyclic MRI contrast agent for effective cancer diagnosis
Biomaterials research, 22(1), 17-17 (2018)
Preparation and evaluation of ZD2 peptide 64Cu-DOTA conjugate as a positron emission tomography probe for detection and characterization of prostate cancer
ACS Omega, 4(1), 1185-1190 (2019)
Synthesis and cytotoxicity evaluation of DOTA-conjugates of ursolic acid
Molecules (Basel), 24(12), 2254-2254 (2019)
Nanomaterials (Basel, Switzerland), 8(6) (2018-06-06)
The control of osteoblast/osteoclast cross-talk is crucial in the bone remodelling process and provides a target mechanism in the development of drugs for bone metabolic diseases. Osteoprotegerin is a key molecule in this biosignalling pathway as it inhibits osteoclastogenesis and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service